Suscriptores   Asóciese  
Textos Completos Autorizados
LA TERAPIA CON AEROSOLES EN EL ASMA BRONQUIAL

v-estudie-lo-mejor.gif
Expertos Invitados





LA TERAPIA CON AEROSOLES EN EL ASMA BRONQUIAL

(especial para SIIC © Derechos reservados)
El cumplimiento y el éxito en el tratamiento del asma no dependen del dispositivo que se utilice para administrar la droga sino de la elección del sistema adecuado para cada caso y de la técnica de inhalación.
sunita9.jpg Autor:
Sunita Sharma
Columnista Experto de SIIC

Institución:
Department of Pharmacology Indira Gandhi Medical College Mayo Hospital Nagpur, India

Artículos publicados por Sunita Sharma
Recepción del artículo
14 de Septiembre, 2004 		Aprobación
3 de Noviembre, 2004
Primera edición
14 de Julio, 2005 		Segunda edición, ampliada y corregida
7 de Junio, 2021

LA TERAPIA CON AEROSOLES EN EL ASMA BRONQUIAL

Resumen
La administración de medicamentos en aerosol es la vía lógica en el tratamiento del asma debido a que la llegada de la droga a la pequeña vía aérea es máxima y los efectos sistémicos no deseados disminuyen al mínimo. Actualmente, la mayoría de las drogas que se utilizan para el manejo del asma están formuladas en aerosol y existen distintos sistemas de administración que dirigen la medicación al paciente, como nebulizadores, inhaladores con dosis medida con espaciador o sin éste, inhaladores de polvo. Aun así es difícil determinar con exactitud a qué lugar del pulmón debe dirigirse la medicación y cuál es el sistema de administración más efectivo. Con el propósito de superar las desventajas de los sistemas de administración en aerosol, se introducen nuevos sistemas. La selección del sistema depende de muchos factores entre los que se incluyen: la edad del paciente, la habilidad para cooperar, la gravedad del asma entre otros. Mientras los estudios demuestran las ventajas de un dispositivo en relación con otro, los expertos recomiendan que la técnica de inhalación es más importante que el dispositivo en sí mismo. Esta revisión ilustra acerca de los diferentes sistemas de administración de aerosoles, sus ventajas y desventajas y ofrece una guía para la selección del sistema de administración más adecuado.

Palabras clave
Aerosoles, asma bronquial, inhaladores


Artículo completo
(castellano)
Extensión:  +/-10.01 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

AEROSOL THERAPY IN BRONCHIAL ASTHMA

Abstract
Aerosol delivery of medication is the logical route for asthma therapy since drug delivery to the small airway is maximized, while undesirable systemic effects are minimized. Currently most classes of drugs used for asthma management are available as aerosol formulation and various aerosol delivery systems which generate and direct aerosols towards the patient are available (i.e. nebulizers, metered dose inhalers with or without spacer and dry powder inhalers). Still, it is difficult to tell exactly where within the lung particular medication is to be targeted and which system will be useful. To overcome the drawbacks in the present aerosol delivery systems new aerosol delivery systems are being introduced. The selection of aerosol delivery system depends on many factors including patient's age, ability to co-operate, asthma severity and others. While studies demonstrated advantages of one device over the other, experts recommend that the technique of inhalation is more important than the device itself. This review therefore highlights different aerosol delivery systems, their advantages and disadvantages and a broad guideline on the selection of the appropriate delivery system.

Key words
Aerosol, bronchial asthma, metered dose inhaler, dry powder inhaler, nebulizer


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Medicina Farmacéutica, Neumonología
Relacionadas: Atención Primaria, Farmacología, Medicina Familiar, Medicina Interna



Comprar este artículo
Extensión: 10.01 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Sharma, Sunita
Patrocinio y reconocimiento:
Agradecimiento: La autora agradece especialmente a Veronica Sprayberry, coordinadora académica del Departamento de Farmacología de UTHSCSA, San Antonio, Texas, por su revisión del inglés.
Bibliografía del artículo
  1. Jain P, Golish JA. Clinical Management of Asthma in the 1990s. Drugs, 1996; 52(Suppl 6):1-11.
  2. Newman SP, Clarke SW. Therapeutic aerosols- Physical and Practical considerations. Thorax, 1983; 38:881-886.
  3. Lemanske RF, Busse WW. Asthma. JAMA, 1997; 278:1855-1873.
  4. Ariyananda PL, Agnew JE, Clarke SW. Aerosol delivery systems for bronchial asthma, PMJ, 1996; 72(845):151-156.
  5. Rebuck AS, Braude AC. Assessment of drug disposition in the lung. Drugs, 1984; 28:544-553.
  6. Newman SP. Aerosol deposition considerations in inhalation therpay. Chest, 1985; 88(2):152s-160s.
  7. Brain JD, Valberg PA. Deposition of aerosol in the respiratory tract. Am Rev Respir Dis, 1979; 120:1325-1373.
  8. Hounman RF, Morgan A. Particle Deposition, In Respiratory Defense Mechanisms (Brain JD, Proctor DF, Reid LM, eds.). New York, Dekker, 1977:125.
  9. Stuart BO. Deposition of inhaled aerosols. Arch Intern Med, 1973; 131:60-73.
  10. Gerrity TR, Lee PS, Hass FJ, et al. Calculated deposition of inhaled particles in the airway generations of normal subjects. J Appl Physiol, 1979; 47:867-873.
  11. Swift DL. Generation and respiratory deposition of therapeutic aerosols. Am Rev Respir Dis, 1980; 122:71-77.
  12. Brain JD, Valber PA. Models of lung retention based on the ICRP Task Group. Arch Environ Health, 1974; 28(1):1-11.
  13. Scherer PW, Haselton FR, Hanna LM, et al. Growth of hygroscopic aerosols in a model of bronchial airways. J Appl Physiol, 1979; 47(3):544.
  14. Lipmann M, Albert RE. The effect of particle size on the regional deposition of inhaled aerosols in the human respiratory tract. Am Ind Hyg Assoc J, 1969; 30:257-275.
  15. Pavia D, Thomson ML, Clarke SW, et al. Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. Thorax, 1977; 32:194-197.
  16. Palmes ED. Measurement of pulmonary air spaces using aerosols. Arch Intern Med, 1973; 131:76-79.
  17. Goldberg IS, Laurenco RV. Deposition of aerosols in pulmonary disease. Arch Intern Med, 1973; 131(1):88-91.
  18. Dolovich MB, Sanchis J, Rossman C, et al. Aerosol penetrance: a sensitive index of peripheral airway obstruction. J Appl Physiol, 1976; 40:468-471.
  19. Kendrick AH, Smith EC, Denyar J. Nebulizers- fill volume, residual volume and matching of nebulizer to compressor. Respir Med, 1995; 89(3):157-159.
  20. Mercer TT. Production of therapeutic aerosols: principles and techniques. Chest, 1981; 80(suppl):818-820.
  21. Clay MM, Clark SW. Wastage of drugs from nebulizers-a review. J R Soc Med, 1987; 80:38-39.
  22. Knoch M, Wunderlich E, Geldner S. A nebulizer system for highly reproducible aerosol delivery. J Aerosol Med, 1994; 7:229-237.
  23. Newham DM, Lipworth BJ. Nebulizer performance, pharmacokinetics airways and systemic effects of salbutamol given via a novel nebulizer delivery system (‘ventstream’). Thorax, 1994; 49:762-770.
  24. Fergusson RJ, Stewart CM, Wathen CG, et al. Effectiveness of nebulized salbutamol administeredi n ambulances to patients with severe acute asthma. Thorax, 1995; 50(1):81-82.
  25. Cook T, Stone G. Paediatric Asthma-a correlation of clinical treatment and oxygen saturation. Hawai Med J, 1995; 54(7):665-668.
  26. Mahakalkar SM, Tibdewal S, Khobragade BP. Cardiopulmonary effects of various anti-asthmatic agents in patients of acute bronchial asthma. The Indian Practitioner, 2002, 55(2):79-85.
  27. Scarfone RJ, Loiselle JM, Wiley JF 2nd, et al. Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children. Ann Emerg Med, 1995; 26(4):480-486.
  28. Konig P. Spacer devices used with metered dose inhalers-Breakthrough or Gimmick Chest, 1985, 88(2):276-284.
  29. Barnes PJ. A new approach to the treatment of asthma. N Engl J Med, 1989; 321:1517-1527.
  30. Newhouse MT, Dolovich MB. Control of asthma by aerosols. N Engl J Med, 1986; 315:870-874.
  31. Summer W, Elston R, Tharpe L, et al. Aerosol bronchodilator delivery methods. Arch Intern Med, 1989; 149,618-623.
  32. Newman SP, Pavia D, Moren F, et al. Deposition of pressurized aerosols in the human respiratory tract. Thorax, 1981; 36:52-55.
  33. Zainudin BM, Biddiscombe M, Tolfree SE, et al. Comparison of bronchodilator reponses and deposition patterns of salbutamol inhaled from a pressurized metered dose inhaler, as a dry powder and as a nebulized solution. Thorax, 1990; 45(6):469-473.
  34. Epstein SW, Manning CPR, Ashley MJ, et al. Survey of clinical use of pressurized aerosol inhalers. Canadian Med Asso J, 1979; 120:813-816.
  35. Demirkan K, Tolley E, Mastin T, et al. Salmeterol administration by metered dose inhaler alone vs metered dose inhaler plus valve holding chamber. Chest, 2000; 117:1314-1318.
  36. Newman SP, Moren F, Pavia D, et al. Deposition of pressurized suspenson aerosols inhaled through extension devices. Am Rev Respir Dis, 1981; 124(3):317-320.
  37. Bisgaard H. A metal aerosol holding chamber devised for young children with asthma. Eur Respir J, 1995; 8(5):856-860.
  38. Bisgaard H, Anhoj J, Klug B, et al. A non-electrostatic spacer for aerosol delivery. Arch Dis Child, 1995; 73(3):226-230.
  39. Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax, 1991; 46:891-894.
  40. Sharma S, Godatwar P, Kulkarni LR. Salbutamol and Beclomethasone Dipropionate in Asthma. Ind J Ped, 2003, 70:129-132.
  41. Newman KB, Milne S, Hamilton C. A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. Chest, 2002; 121:1036-1041.
  42. Hauck HR. Do metdical CFCs, threaten the environment J Aerosol med, 1991; 4:169-174.
  43. Leach CL. Approaches and challenges to use freon propellant replacements. J Aerosol Med, 1993; 6:231.
  44. Juniper E, Buist S, The Study Group. Health related quality of life in moderate asthma. 400 μg hydrofluoroalkane beclomethansone dipropionate vs 800 μg chlorofluorocarbon beclomethasone dipropionate. Chest, 1999; 116:1297-1303.
  45. Langley SJ, Hoden J, Derham A, et al. Fluticasone propionate via the diskhaler or hydrofluoroalkane-13a metered-dose inhaler on methacholine induced airway hyperresponsiveness. Chest, 2002; 122:806-811.
  46. Clark DJ, Lipworth BJ. Lung bioavailability of chlorofluorocarbon free, dry powder and chloroflurocarbon containing formulations of salbutamol. Br J Clin Pharmacol, 1996; 41(3):247-249.
  47. Juniper EF, Price DB, Stampone PA, et al. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extra-fine beclomethasone dipropionate. Chest, 2002; 121:1824-1832.
  48. Tashkin DP. Extra-fine corticosteroid aerosols from hydrofluoroalkane-134a metered dose inhaler. Chest, 1999; 115:316-318.
  49. Ogren RA, Baldwin JL, Simon RA. How patients determine when to replace their metered-dose inhalers. Ann Allerg, 1995; 75:485-489.
  50. Wong CS, Pavord ID, Williams J, et al. Bronchodilator, cardiovascular and hypokalemic effects of fenoterol, salbutamol and terbutaline in asthma. Lancet, 1990; 336:1396-1399.
  51. Barbato A, Cracco A, Tormena F. The first 20 minutes after a single dose of inhaled salmeterol in asthmatic children. Allergy, 1995; 50(6):506-510.
  52. Van Noord JA, Smeets JJ, Raaijmakers JH, et al. Salmeterol versus formeterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J, 1996; 9(8):1684-1688.
  53. Bierman CW, Kemp JP, Nathan RA. Efficacy and safety of inhaled bitolterol mesylatate via metered dose inhaler in children with asthma. Ann Allergy Asthma mmunol, 1996; 76(1):27-35.
  54. Brown PH, Blundell G, Greening AP, et al. Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids Thorax, 1990; 45:736-739.
  55. Pavord I, Knox A. Pharmacokinetic optimisation of inhaled steroid therapy in asthma. Clin Pharmacokinet, 1993; 25(2):126-135.
  56. Holliday SM, Faultds D, Sorkin EM. Inhaled fluticsone propionate: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in asthma. Drugs, 1994; 47(2):318-331.
  57. Clark AR. Medical aerosol inhalers: past, present and future. Aerosol Sci Tech, 1995; 22:374-391.
  58. Croner S, Hedenskog S, Kjellman, N, et al. Salbutamol by powder or spray inhalation in childhood asthma. Allergy, 1980; 35(7):589-592.
  59. Cochrane MG, Bala MV, Downs KE, et al. Inhaled corticosteroids for asthma therapy. Chest, 2000; 117:542-550.
  60. Lofdahl CG, Andersson L, Bondesson E, et al. Difference in bronchodilating potency of salbutamol in Turbuhaler as compared with a pressurized metered dose inhaler formulation in patients with reversible airway obstruction. Eur Respir J, 1997; 10:2474-2478.
  61. Olsson B, Asking L. Critical aspect of the function of inspiratory flow driven inhalers. J Aerosol Med, 1994; 7(suppl):43-47.
  62. Newman SP, Clarke SW. Inhalation devices and techniques-In: Asthma, (Clark T, Godfrey S, Lee T, eds.) 3rd edition, 1992, Chapman and Hall London, 469-502.
  63. Serafin WE. Drugs used in the treatment of asthma. In: Goodman and Gilman’s The Pharmacological basis of therapeutics (Hardman JG, Limbird LE, et al eds.) 9th edition, New York, Mc Graw Hill, 1996:659-682.
  64. Wong CS, Cooper S, Britton JR, et al. Steroid sparing effect of nedocromil sodium in asthmatic patients on high doses of inhaled steroids. Clin Exp Allergy, 1993; 23:370-376.
  65. Bronsky EA, Spector SL, Pearlman DS, et al. Albuterol aerosol versus albuterol rotacaps in exercised-induced bronchospasm in children. J Asthma, 1995; 32(3):207-214.
  66. Thorsson L, Edsbacker S, Conrodson TB. Lung deposition of budesonide from turbuhaler is twice that from a pressurized metered dose inhaler. Eur Respir J, 1994; 7:1839-1844.
  67. Newman S, Steed K, Hooper G, et al. Comparison of gamma camera scintigraphy and pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler. Pharm Res, 1995; 12:231-236.
  68. Fulsang G, Pederson S. Comparison of a new multidose powder inhaler with a pressurized aerosol in children with asthma. Paediatr Pulmonol, 1989; 7:112-115.
  69. Tibdewal S, Mahakalkar SM, Khobragade BP, Khanzode SD. Effect of Various antiasthmatic agents on serum electrolytes and blood sugar levels- A clinical study. Indian Medical Gazette, 2000; 134(9):285-290.
  70. Nelson H, Kemp JP, Bieler S, et al. Comparative efficacy and safety of albuterol sulfate spiros inhaler and albuterol metered dose inhaler in asthma. Chest, 199; 115:329-335.
  71. Newhouse MT, Nantel NP, Chambers CB, et al. Clickhaler (a novel dry powder inhaler) provides similar bronchodilatation to pressurized metered dose inhaler, even at low flow rates. Chest, 1999; 115:952-956.
  72. Ram FSF, Wright J, Brocklebank D, et al. Systematic review of clinical effectiveness of pressurized metered dose inhalers versus other hand held inhaler devices for delivering beta2-agonists bronchodilators in asthma. BMJ, 2001; 323:901.
  73. Giannini D, Franco AD, Bacci E, et al. The protective effect of salbutamol inhaled using different devices on methacholine bronchoconstriction. Chest, 2000; 117:1319-1323.
  74. Cochrane GM. Compliance and outcomes in patients with asthma. Drugs, 1996; 52:12-19.
  75. Barry PW, O’Callaghan C. Asthma drug delivery devices for children. BMJ, 200; 320:664.
  76. Georgitis JW. The 1997 Asthma Management Guidelines and therapeutic issues relating to the treatment of asthma. Chest, 1999; 115:210-217.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Acerca de SIIC   Estructura de SIIC   Fuentes informativas  

Sociedad Iberoamericana de Información Científica

Copyright siicsalud© 1997-2024 ISSN siicsalud: 1667-9008
ua31517